Screening Methods for Antiepileptic Drugs

Screening Methods for Antiepileptic Drugs

1. Definition, rationale & the screening problem

• Epilepsy is a chronic disorder characterised by recurrent unprovoked seizures; a seizure is the paradoxical event of abnormal, excessive, hypersynchronous discharge from an aggregate of CNS neurons (SK Gupta 3e Ch.28, p.412).
• Pathophysiologically, seizures reflect an imbalance in voltage-dependent ion channels — reduced inhibitory (GABA-mediated) or increased excitatory (glutamate-mediated) drive (SK Gupta 3e Ch.28, p.412).
• Drug therapy of epilepsy is empirical and does not address underlying pathology; despite many efficacious AEDs, ~25% of absence and ~15% of generalised tonic-clonic patients remain inadequately controlled, and 20–30% of epilepsy becomes drug-resistant — driving the need for better preclinical models, especially for pharmacoresistant epilepsy (SK Gupta 3e Ch.28, p.412; Vogel 4e V2 p.1216, p.1272).
• Central caveat repeated across all sources: most "screening models" are models of seizures, not of epilepsy — they evoke acute provoked seizures in a normal brain (electroshock/chemoconvulsant), whereas human epilepsy is chronic spontaneous recurrent seizures. Genetic and chronic post-status models come closest to true epilepsy (SK Gupta 3e Ch.28, p.430; Medhi Ch.18, p.192).
• Purpose of a screening cascade: (i) detect anticonvulsant activity, (ii) define the spectrum (which human seizure type), (iii) probe mechanism, (iv) detect epileptogenesis-modifying / disease-modifying potential, (v) identify activity in drug-resistant models, and (vi) flag neurotoxicity/therapeutic index — no single test predicts the full profile, so a battery is mandatory (SK Gupta 3e Ch.28, p.430).
• 2002 NIH/NINDS/AES Models Workshop recommended discovery of newer genetic models and injury-induced epilepsy models (electrically/chemically induced status epilepticus) to find therapies for pharmacoresistant and disease-modifying targets (SK Gupta 3e Ch.28, p.412).

Characteristics of an "ideal" epilepsy model (validity benchmark)

• Development of spontaneously occurring seizures.
• Seizure type resembling that seen in human epilepsy (construct/face validity).
• EEG correlates of epileptic-like activity.
• Age-dependency of onset, as in many human epileptic syndromes.
• No current model satisfies all criteria; genetic animal models come closest (resemble idiopathic human epilepsy) and are especially valuable for drug-resistant epilepsy (SK Gupta 3e Ch.28, p.430).